Background
Methods
Ethics statement
Participants
Clinical and neuropsychological assessment
Serum measurement
Statistical analysis
Results
Demographic characteristics and clinical features of participants
Male (n = 268) | Female (n = 187) | |||||
---|---|---|---|---|---|---|
Cognition impairment group (n = 219) | Cognition normal group (n = 49) | P value | Cognition impairment group (n = 148) | Cognition normal group (n = 39) | P value | |
Age (years) | 48.68 ± 11.71 | 37.10 ± 11.57 | < 0.001* | 47.84 ± 13.78 | 33.90 ± 10.97 | < 0.001* |
BMI (kg/m2) | 24.57 ± 3.66 | 24.76 ± 3.92 | 0.749 | 24.25 ± 3.77 | 24.72 ± 4.34 | 0.53 |
Education (years) | 9.70 ± 3.12 | 12.76 ± 3.06 | < 0.001* | 9.74 ± 3.86 | 13.21 ± 2.60 | < 0.001* |
Hypertension (yes/no) | 30/189 | 0/49 | 0.002* | 8/140 | 2/37 | 1.000 |
Diabetes mellitus (yes/no) | 19/200 | 3/46 | 0.764 | 8/140 | 0/39 | 0.208 |
Total disease duration (months) | 264.68 ± 142.16 | 157.12 ± 135.05 | < 0.001* | 232.57 ± 167.08 | 122.20 ± 111.92 | < 0.001* |
Total PANSS score | 61.52 ± 17.54 | 61.00 ± 19.45 | 0.672 | 69.72 ± 18.91 | 55.31 ± 16.318 | < 0.001* |
TBIL (μmol/L) | 11.02 ± 4.77 | 14.98 ± 8.75 | 0.001* | 10.68 ± 4.22 | 9.96 ± 6.04 | 0.054 |
TC (mmol/L) | 4.46 ± 0.90 | 4.59 ± 0.81 | 0.095 | 4.54 ± 0.89 | 4.68 ± 1.36 | 0.696 |
TG (mmol/L) | 1.65 ± 1.24 | 1.74 ± 1.11 | 0.467 | 1.43 ± 0.92 | 2.08 ± 5.14 | 0.634 |
LDL (mmol/L) | 2.82 ± 0.76 | 2.98 ± 0.84 | 0.169 | 2.74 ± 1.05 | 2.58 ± 0.75 | 0.351 |
HDL (mmol/L) | 1.04 ± 0.26 | 1.29 ± 1.33 | 0.046* | 1.32 ± 0.40 | 1.36 ± 0.27 | 0.220 |
Mean chlorpromazine equivalent (mg) | 628.08 ± 379.8 | 578.97 ± 314.36 | 0.528 | 645.08 ± 378.02 | 614.42 ± 308.44 | 0.821 |
Association between serum TBIL level and cognition stratified by sex
Male (n = 268) | Female (n = 187) | |||||||
---|---|---|---|---|---|---|---|---|
Univariate Results | Multivariate Results | Univariate Results | Multivariate Results | |||||
OR (95%CI) | P value | OR (95%CI) | P value | OR | P value | OR | P value | |
Age (years) | 1.079 (1.050–1.110) | < 0.001* | 1.064(1.032–1.098) | < 0.001* | 1.079(1.047–1.112) | < 0.001* | 1.061(1.026–1.098) | 0.001* |
BMI (kg/m2) | 0.986 (0.908–1.072) | 0.748 | – | – | 0.970(0.886–1.061 | 0.499 | – | – |
Education (years) | 0.719 (0.637–0.812) | < 0.001* | 0.729(0.640–0.831) | < 0.001* | 0.755(0.671–0.851) | < 0.001* | 0.831(0.728–0.950) | 0.007* |
Hypertension (yes/no) | NA | 0.998 | – | – | 1.057(0.215–5.191) | 0.945 | – | – |
Diabetes mellitus (yes/no) | 1.457 (0.414–5.131) | 0.558 | – | – | NA | 0.999 | – | – |
Total disease duration (months) | 1.006 (1.003–1.008) | < 0.001* | NA | 0.978 | 1.005(1.002–1.008) | < 0.001* | NA | 0.311 |
Total PANSS score | 1.002 (0.984–1.019) | 0.853 | – | – | 1.053(1.027–1.079) | < 0.001* | 1.042 (1.015–1.070) | 0.002* |
TBIL (μmol/L) | 0.906 (0.861–0.955) | < 0.001* | 0.931(0.873–0.992) | 0.027* | 1.037(0.954–1.127) | 0.390 | NA | 0.447 |
TC (mmol/L) | 0.847 (0.605–1.186) | 0.335 | – | – | 0.876(0.624–1.228 | 0.442 | – | – |
TG (mmol/L) | 0.944 (0.747–1.192) | 0.626 | – | – | 0.922(0.802–1.059) | 0.249 | – | – |
LDL (mmol/L) | 0.781 (0.529–1.153) | 0.213 | – | – | 1.217(0.782–1.896) | 0.384 | – | – |
HDL (mmol/L) | 0.418 (0.127–1.381) | 0.153 | – | – | 0.756(0.302–1.894) | 0.551 | – | – |
Mean chlorpromazine equivalent (mg) | 1.000 (0.999–1.001) | 0.399 | – | – | 1.000(0.999–1.001) | 0.639 | – | – |
Association between serum TBIL levels and cognitive function after PSM analysis
Male (n = 98) | Female (n = 78) | |||||
---|---|---|---|---|---|---|
Cognition impairment group (n = 49) | Cognition normal group (n = 49) | P value | Cognition impairment group (n = 39) | Cognition normal group (n = 39) | P value | |
Age (years) | 38.43 ± 11.90 | 37.10 ± 11.57 | 0.513 | 35.79 ± 11.10 | 33.90 ± 10.97 | 0.415 |
BMI (kg/m2) | 24.55 ± 3.96 | 24.76 ± 3.92 | 0.989 | 24.44 ± 3.23 | 24.72 ± 4.34 | 0.845 |
Education (years) | 12.16 ± 3.23 | 12.76 ± 3.06 | 0.568 | 13.15 ± 3.65 | 13.21 ± 2.60 | 0.848 |
Hypertension (yes/no) | 0/49 | 0/49 | 1 | 3/36 | 2/37 | 1 |
Diabetes mellitus (yes/no) | 2/47 | 3/46 | 1 | 0/39 | 0/39 | 1 |
Total disease duration (months) | 171.14 ± 110.28 | 157.12 ± 135.05 | 0.325 | 138.76 ± 135.27 | 122.20 ± 111.92 | 0.905 |
Total PANSS score | 61.35 ± 20.11 | 61.00 ± 19.45 | 0.904 | 62.21 ± 17.77 | 55.31 ± 16.32 | 0.049* |
TBIL (μmol/L) | 11.05 ± 5.01 | 14.98 ± 8.75 | 0.03* | 11.87 ± 4.72 | 9.96 ± 6.04 | 0.015* |
TC (mmol/L) | 4.47 ± 0.98 | 4.59 ± 0.81 | 0.134 | 4.57 ± 0.89 | 4.68 ± 1.36 | 0.916 |
TG (mmol/L) | 1.80 ± 1.80 | 1.74 ± 1.11 | 0.654 | 1.52 ± 0.88 | 2.08 ± 5.14 | 0.325 |
LDL (mmol/L) | 2.80 ± 0.81 | 2.98 ± 0.84 | 0.134 | 2.83 ± 1.65 | 2.58 ± 0.75 | 0.853 |
HDL (mmol/L) | 1.09 ± 0.29 | 1.29 ± 1.33 | 0.601 | 1.38 ± 0.46 | 1.36 ± 0.27 | 0.503 |
Mean chlorpromazine equivalent (mg) | 542.84 ± 350.92 | 578.97 ± 314.36 | 0.611 | 644.79 ± 320.76 | 614.42 ± 308.44 | 0.671 |
male (n = 98) | female (n = 78) | |||||||
---|---|---|---|---|---|---|---|---|
Univariate Results | Multivariate Results | Univariate Results | Multivariate Results | |||||
OR (95%CI) | P value | OR (95%CI) | P value | OR | P value | OR | P value | |
Age (years) | 1.010(0.976–1.045) | 0.573 | – | – | 1.015(0.976–1.056) | 0.460 | – | – |
BMI (kg/m2) | 0.986(0.891–1.092) | 0.790 | – | – | 0.981(0872–1.103) | 0.745 | – | – |
Education (years) | 0.939(0.825–1.070) | 0.345 | – | – | 0.995(0.863–1.072) | 0.942 | – | – |
Hypertension (yes/no) | NA | 1 | – | – | 1.542(0.243–9.776) | 0.646 | – | – |
Diabetes mellitus (yes/no) | 1.533(0.245–9.600) | 0.648 | – | – | NA | 1.000 | – | – |
Total disease duration (months) | 1.001(0.998–1.004) | 0.571 | – | – | 1.001(0.997–1.005) | 0.552 | – | – |
Total PANSS score | 1.001(0.981–1.021) | 0.930 | – | – | 1.025(0.996–1.055) | 0.086 | 1.025(0.996–1.055) | 0.086 |
TBIL (μmol/L) | 0.909 (0.841–0.983) | 0.016* | 0.909 (0.841–0.983) | 0.016* | 1.074(0.979–1.178) | 0.133 | NA | 0.133 |
TC (mmol/L) | 0.852(0.543–1.337) | 0.486 | – | – | 0.920(0.618–1.368) | 0.679 | – | – |
TG (mmol/L) | 1.030(0.786–1.348) | 0.831 | – | – | 0.951(0.813–1.113) | 0.534 | – | – |
LDL (mmol/L) | 0.767(0.466–1.260) | 0.295 | – | – | 1.191(0.786–1.805) | 0.410 | – | – |
HDL (mmol/L) | 0.701(0.279–1.759) | 0.449 | – | – | 1.123 (0.336–3.752) | 0.851 | – | – |
Mean chlorpromazine equivalent (mg) | 1.000(0.998–1.001) | 0.589 | 1.000(0.999–1.002) | 0.667 |